Drug Profile
Research programme: metabolic disorders therapy - Astex Therapeutics/Mitsubishi Tanabe Pharma
Alternative Names: Metabolic disorders therapy research programme - Astex Therapeutics/Mitsubishi Tanabe PharmaLatest Information Update: 26 May 2010
Price :
$50
*
At a glance
- Originator Astex Therapeutics; Mitsubishi Pharma Corporation
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Metabolic disorders
Most Recent Events
- 26 May 2010 Discontinued - Preclinical for Metabolic disorders in United Kingdom (unspecified route)
- 23 May 2006 This programme is still in active development
- 10 Jun 2003 Preclinical trials in Metabolic disorders in United Kingdom (unspecified route)